A Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Clinical Efficacy and Safety of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Clinical Efficacy and Safety of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2017

At a glance

  • Drugs Complement C1 inhibitor protein (Primary)
  • Indications Hereditary angioedema
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPACT
  • Sponsors CSL Behring
  • Most Recent Events

    • 29 Oct 2017 According to a CSL Behring media release, subgroup analysis of data from this trial (n = 21) was presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.
    • 24 Oct 2017 According to a CSL Behring media release, new sub-analyses from this trial will be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.
    • 23 Jun 2017 According to a CSL Behring media release, U.S. Food and Drug Administration (FDA) has approved HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]), the first and only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.This approval is supprted by the data from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top